Collegium to present Phase 4 AZSTARYS studies in children with ADHD
COLL•Collegium Pharmaceutical will present seven ADHD research abstracts at two conferences in October and November 2026, including pediatric Phase 4 studies of AZSTARYS and real-world research on adult Jornay PM treatment.
1. Conference presentations
Collegium Pharmaceutical will present seven ADHD research abstracts at AACAP’s annual meeting on October 26-31, 2026, and NEI’s congress on November 5-8. Pediatric Phase 4 studies examine AZSTARYS’ safety, tolerability and efficacy, including in children aged 4-5.
2. Jornay PM research
Real-world research examines adult Jornay PM treatment persistence, morning functioning and caregiver strain. Investigators characterize the observational findings as hypothesis-generating.
